Newlimit, the anti-aging biotech co-founded by Coinbase Global Inc. (Nasdaq: COIN) Chief Executive Brian Armstrong, has closed a $435 million Series C funding round, the company announced on June 2. The raise was led by Founders Fund and roughly tripled Newlimit’s post-money valuation to about $3.1 billion, up from a mark that sat below $1 billion at its previous round.

Image source: X

The financing drew a roster of high-profile backers, including new investors like Thrive Capital, Greenoaks, and Quiet Capital. Returning supporters included Kleiner Perkins, Abstract, and Valor Equity Partners, each of whom added to their existing stakes.

Founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Mark Kimmel, Newlimit is built on a single thesis, i.e. aging is “plastic,” or reversible, at the cellular level. The company develops medicines designed to restore youthful function to old cells through epigenetic reprogramming, a technique that aims to reset how genes are expressed without altering the underlying DNA.

Newlimit has grown quickly and the numbers spell that quite clearly. The startup raised $130 million as recently as last year, meaning the new round more than triples its valuation in roughly twelve months. The company has said the accelerated timeline was driven by a prototype medicine breakthrough that reverses cell age in old human liver cells, giving the team confidence to push toward the clinic.

That progress sets up the company’s most important milestone yet, as Newlimit said it plans to bring its first aging-reprogramming medicine into human clinical trials next year, a step that will move the firm from laboratory research into regulated drug development.

Moreover, epigenetic reprogramming, the science underpinning Newlimit, has become one of the most closely watched and heavily funded areas of biotechnology. The approach builds on Nobel-winning research showing that mature cells can be coaxed back toward a younger state, and a wave of startups has raced to turn that insight into therapies. Newlimit’s latest raise places it among the best-capitalized names in the field.

For Armstrong, the round highlights a portfolio that now stretches well beyond Coinbase. He has used his crypto fortune to back ambitious science and infrastructure projects, framing longevity as one of the defining technological challenges of the era. Bitcoin.com News has reported on Armstrong’s running commentary about modernizing finance and the broader onchain economy, and his biotech bet runs on a parallel track of long-horizon, high-risk investing.

The Founders Fund-led round also reflects renewed investor appetite for moonshot biotech at a time when crypto markets have been wobbling. Backers are betting that breakthroughs in cellular reprogramming could eventually produce treatments for age-related disease, a market measured in the trillions if the science delivers.

The next test is the clinic and Newlimit’s move into human trials next year will be the first real-world read on whether its laboratory results translate into safe, effective medicines.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。